Bi-specific T-cell engager

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Tuesday, March 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: Insights On 10 Current & Potential Proprietary Platforms, Company, Indication & Phase for 15 Drugs, and 14 Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 1, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Carcinoma, Ligand, SCLC, Indication, Novartis, History, Therapy, Chugai Pharmaceutical Co., FDA, DLL3, AbbVie, Boehringer Ingelheim, Malignancy, Bladder cancer, Amgen, Cancer, Bi-specific T-cell engager, Growth, Pharmaceutical industry

The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024 Report Finding & Highlights:
    Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms: > 10 Platform
    DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: > 15 Drugs
    Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14 Companies
    In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape.
  • Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies.
  • The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates.

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Boehringer, Trichloroethylene, Acquisition, Innovation, Ingelheim am Rhein, Potyvirus, Boehringer Ingelheim, Tissue, Cancer, Innovation Unit, Patient, Bi-specific T-cell engager, Bacteria, Immunotherapy, CHF, Pharma, Fine chemical, Vaccine, Allschwil

Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.

Key Points: 
  • Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF.
  • T3 Pharma has developed a proprietary therapy platform that uses live bacteria to deliver immune-modulating proteins to cancer cells and tumor micro-environments.
  • “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs.
  • Boehringer Ingelheim is adopting a comprehensive approach to cancer therapy development including both cancer cell-directed and immuno-oncology approaches.

Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress

Retrieved on: 
Tuesday, December 12, 2023
Pancreatic cancer, Trae tha Truth, Safety, Progression-free survival, Gallbladder cancer, PD, Clinical trial, ESMO, Patient, Multimedia, PFS, Bi-specific T-cell engager, Pharmacokinetics, DCR, Index, ORR, Nausea, MTD, Phase, Stomach, Infrared spectroscopy correlation table, Neoplasm, Fever, CD3, Cytokine release syndrome, Pharmaceutical industry

QLS31905, developed by Qilu Pharmaceutical, is a bispecific T cell engager (BiTE) that targets Claudin18.2.

Key Points: 
  • QLS31905, developed by Qilu Pharmaceutical, is a bispecific T cell engager (BiTE) that targets Claudin18.2.
  • The primary objective of this trial was to evaluate the safety, tolerability, and preliminary antitumor activity of QLS31905 in patients with advanced solid tumors.
  • During the dose-escalation phase, 22 participants received QLS31905 at 0.5 μg/kg QW to 350 μg/kg QW.
  • The Phase II clinical trial are now in progress to further assess the efficacy and safety of QLS31905.

Applied BioMath, LLC Presents Quantitative Systems Pharmacology Model of T-cell Engagers for Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, October 30, 2023
American Board of Applied Toxicology, Mathematical and theoretical biology, Trial of the century, Therapy, Bivalent (genetics), Doctor of Philosophy, QSP, R, Mall of America, SITC, Immunotherapy, Bi-specific T-cell engager, Engagers, Drug discovery, Trichloroethylene, Society, Cancer, Therapeutic index, Pharmaceutical industry, Vaccine

During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."

Key Points: 
  • During the conference, Fei Hua, PhD, Vice President of Modeling and Simulation Services at Applied BioMath, will present the poster entitled, "Overcoming the dose-response prediction limitation from bench to clinic for T-cell engagers: Using Quantitative Systems Pharmacology (QSP) modeling in the development of CDR404 for solid tumors."
  • While T-cell Engagers (TCEs) offer a potentially very potent approach to treat cancer, they also have complex relationships between binding potency, exposure, and efficacy.
  • "For therapeutics with complex mechanisms of action (MoA), QSP modeling can be integral for progressing through the R&D pipeline," said John Burke, PhD, Co-founder, President and CEO.
  • "Particularly for TCEs, we've had experience where QSP modeling has tested target feasibility, optimized molecule design, predicted therapeutic index, and guided clinical trial design."

Applied BioMath, LLC Announces Participation at AAPS 2023 PharmSci 360

Retrieved on: 
Thursday, October 19, 2023
Drug development, Science, Patient, Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, CSO, Bi-specific T-cell engager, Simulation, Doctor of Philosophy, AAPS, R, National Center for Advancing Translational Sciences, Messenger, UGT1A1, Biomarker, Translation, Crigler–Najjar syndrome, Pharmaceutical industry, Medical imaging, Management, Medical device

CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.

Key Points: 
  • CONCORD, Mass., Oct. 19, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at AAPS 2023 PharmSci 360 occurring October 22-25, 2023 in Orlando, FL.
  • Applied BioMath will participate in multiple presentations during the conference.
  • Joshua Apgar, PhD, Co-founder and CSO at Applied BioMath will give a Speaker Spotlight presentation entitled, "Evolving Clinical Pharmacology and Translational PK/PD Approaches for New Modalities" on Tuesday, October 24th from 9:30-10:30am.
  • To learn more about Applied BioMath, visit www.appliedbiomath.com .

Claudin 18.2-Targeted Immunotherapy Research Report 2023: Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 27, 2023
Health, Pharmaceutical, Incidence, Partnership, ADCC, Bi-specific T-cell engager, TCE, Hook effect, Overalls, Survival, Big Pharma, Business, Research, Appetite, History, Immunotherapy, Zolbetuximab, CDC, Vomiting, CAR, Science, Patient, Corporation, Antibody, Cancer, European, ADCP, Spacecraft, BDL, R, Stomach, GLOW, III, Bispecific monoclonal antibody, Safety, Sales, Vaccine, Pharmaceutical industry, Fine chemical, Risk management, Medical imaging, Dietary supplement

The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive report offers valuable insights into the world of claudin 18.2 (CLDN18.2)-targeted antibody and cell therapy candidates, as of August 2023.
  • You'll delve into the industry landscape surrounding innovative claudin18.2-targeted antibody and cell therapy candidates.
  • The report shines a light on 48 companies actively engaged in research and development within this field, highlighting 68 unique product candidates.

Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer

Retrieved on: 
Wednesday, August 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Micrometer (device), Industrial engineering, Teva Pharmaceuticals, KRAS, Partnership, University, Therapy, University of California, Irvine School of Medicine, Bi-specific T-cell engager, Bachelor of Technology, Cancer, MBA, Protein Sciences, Acquisition, Motilal Nehru National Institute of Technology Allahabad, Carnegie Mellon University, Catena, Growth, Merck, Commercial, Kite Pharma, Imagination, Saurabh, PARP, Management, Fine chemical, Amgen, Bayer, Chemistry, Medicine

Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.

Key Points: 
  • Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments.
  • The company has appointed Saurabh Johri as Chief Business Officer and Rick Kendall, Ph.D., as Chief Scientific Officer.
  • “Catena is in an exciting phase of growth, and we are pleased to welcome Saurabh and Rick to our growing team.
  • Saurabh joins Catena Biosciences from Bayer where he was most recently Vice President & Global Head, Oncology Strategy and Early Commercialization.

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bispecific monoclonal antibody, Monoclonal antibody, MOA, B-cell lymphoma, Therapy, CD3, CD20, Bi-specific T-cell engager, DLBCL, Roche, Cancer, Research, Antibody, Trial of the century, Patient, Location, Growth, Health Canada, Vaccine, Indication

The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
    Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
    The introduction of antibody-based therapeutics has been a game changer in the field of cancer therapy.
  • The continued expansion in research and development of antibody biologics has brought in the era of bispecific antibodies.
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
    15.